Head and Neck Cancer Symposium - October 8, 2021

This symposium will bring basic scientists and clinicians together to discuss the latest developments in Head & Neck Cancer research and therapy.

Target Audience

Target audience:

  • Otolaryngology / Head and Neck Surgery
  • Medical Oncology
  • Radiation Oncology
  • Surgical Oncology
  • Oral and Maxillofacial Surgery
  • Oral and Maxillofacial Radiology
  • Oral and Maxillofacial Pathology
  • Dental Public Health
  • Head & Neck Cancer Researchers

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe current research on the etiology, pathogenesis, metastasis and treatment of head and neck cancer;
  2. Apply innovative therapeutic approaches to the treatment of head and neck cancer patients with particular emphasis on immunotherapy and precision medicine;
  3. Identify the translational gap whereby advances in research are not translated into clinical applications that directly benefit patient health.
Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 7.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 7.75 Participation
Course opens: 
10/08/2021
Course expires: 
10/07/2022
Rating: 
0

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring activity for a maximum of 7.75 AMA PRA Category 1 Credits ™.   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 7.75 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 7.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 7.75 Participation

This educational activity is supported by an educational grant from GlaxoSmithKline.

This activity has been provided in part by an unrestricted educational grant from Medtronic.

This educational activity is supported by an educational grant from Olympus.

Please login or register to take this course.